Skip to main content
Shampa Das

Professor Shampa Das
BSc, PhD

Publications

What type of publication do you want to show?

2024

Population pharmacokinetics/pharmacodynamics of minocycline plus rifampicin in patients with complicated skin and skin structure infections caused by MRSA.

Pardos, S. L., Hope, W., Kotsaki, A., Das, S., Giamarellos-Bourboulis, E. J., Kontopoulouk, T., . . . MacGowan, A. P. (2024). Population pharmacokinetics/pharmacodynamics of minocycline plus rifampicin in patients with complicated skin and skin structure infections caused by MRSA.. The Journal of antimicrobial chemotherapy, dkae363. doi:10.1093/jac/dkae363

DOI
10.1093/jac/dkae363
Journal article

<i>Acinetobacter baumannii</i> transformants expressing oxacillinases and metallo-β-lactamases that confer resistance to meropenem: new tools for anti-<i>Acinetobacter</i> drug development and AMR preparedness.

Dubey, V., Farrington, N., Harper, N., Johnson, A., Horner, I., Stevenson, A., . . . Hope, W. (2024). <i>Acinetobacter baumannii</i> transformants expressing oxacillinases and metallo-β-lactamases that confer resistance to meropenem: new tools for anti-<i>Acinetobacter</i> drug development and AMR preparedness.. Antimicrobial agents and chemotherapy, 68(10), e0022224. doi:10.1128/aac.00222-24

DOI
10.1128/aac.00222-24
Journal article

Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation.

Das, S., Riccobene, T., Carrothers, T. J., Wright, J. G., MacPherson, M., Cristinacce, A., . . . Raber, S. (2024). Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation.. European journal of clinical pharmacology, 80(4), 529-543. doi:10.1007/s00228-023-03609-x

DOI
10.1007/s00228-023-03609-x
Journal article

2022

Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings

Darlow, C. A., McEntee, L., Johnson, A., Farrington, N., Unsworth, J., Jimenez-Valverde, A., . . . Hope, W. (2022). Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(12), 3349-3357. doi:10.1093/jac/dkac323

DOI
10.1093/jac/dkac323
Journal article

Expected phenotypes and expert rules are important complements to antimicrobial susceptibility testing Comment

Gatermann, S., Das, S., Dubreuil, L., Giske, C. G., Kahlmeter, G., Lina, G., . . . Canton, R. (2022). Expected phenotypes and expert rules are important complements to antimicrobial susceptibility testing Comment. CLINICAL MICROBIOLOGY AND INFECTION, 28(6), 764-767. doi:10.1016/j.cmi.2022.03.007

DOI
10.1016/j.cmi.2022.03.007
Journal article

Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance

Darlow, C. A., Farrington, N., Johnson, A., McEntee, L., Unsworth, J., Jimenez-Valverde, A., . . . Hope, W. (2022). Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(5), 1334-1343. doi:10.1093/jac/dkac038

DOI
10.1093/jac/dkac038
Journal article

Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance

Farrington, N., McEntee, L., Johnson, A., Unsworth, J., Darlow, C., Jimenez-Valverde, A., . . . Hope, W. (2022). Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 66(4). doi:10.1128/aac.02181-21

DOI
10.1128/aac.02181-21
Journal article

2021

Comparing probability of target attainment against <i>Staphylococcus aureus</i> for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models

Cristinacce, A., Wright, J. G., Macpherson, M., Iaconis, J., & Das, S. (2021). Comparing probability of target attainment against <i>Staphylococcus aureus</i> for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 99(4). doi:10.1016/j.diagmicrobio.2020.115292

DOI
10.1016/j.diagmicrobio.2020.115292
Journal article

Reply to Asempa et al., "The Ongoing Challenge with NDM-Harboring <i>Enterobacteriaceae</i> in Murine Infection Models"

Das, S., Everett, M., Zalacain, M., & Hope, W. (2021). Reply to Asempa et al., "The Ongoing Challenge with NDM-Harboring <i>Enterobacteriaceae</i> in Murine Infection Models". ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 65(2). doi:10.1128/AAC.02249-20

DOI
10.1128/AAC.02249-20
Journal article

2020

Re: In the name of common sense: EUCAST breakpoints and potential pitfalls. National dissemination of EUCAST guidelines is a shared responsibility

Kahlmeter, G., Canton, R., Giske, C. G., & Turnidge, J. (2020). Re: In the name of common sense: EUCAST breakpoints and potential pitfalls. National dissemination of EUCAST guidelines is a shared responsibility. CLINICAL MICROBIOLOGY AND INFECTION, 26(12), 1692-1693. doi:10.1016/j.cmi.2020.08.008

DOI
10.1016/j.cmi.2020.08.008
Journal article

Pharmacodynamics of the Novel Metallo-beta-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae

Das, S., Johnson, A., McEntee, L., Farrington, N., Kirby, A., Unsworth, J., . . . Hope, W. (2020). Pharmacodynamics of the Novel Metallo-beta-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 64(11). doi:10.1128/AAC.01076-20

DOI
10.1128/AAC.01076-20
Journal article

Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae.

Das, S., Johnson, A., McEntee, L., Farrington, N., Kirby, A., Unsworth, J., . . . Hope, W. (2020). Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae.. Antimicrob Agents Chemother, 64(11). doi:10.1128/AAC.01076-20

DOI
10.1128/AAC.01076-20
Journal article

Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing <i>Klebsiella pneumoniae</i>

Johnson, A., McEntee, L., Farrington, N., Kolamunnage-Dona, R., Franzoni, S., Vezzelli, A., . . . Hope, W. (2020). Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing <i>Klebsiella pneumoniae</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(6). doi:10.1128/AAC.00180-20

DOI
10.1128/AAC.00180-20
Journal article

Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam

Li, J., Lovern, M., Riccobene, T., Carrothers, T. J., Newell, P., Das, S., . . . Tawadrous, M. (2020). Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(4). doi:10.1128/AAC.02105-19

DOI
10.1128/AAC.02105-19
Journal article

2019

Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil

Li, J., Das, S., Zhou, D., & Al-Huniti, N. (2019). Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 8(5), 682-694. doi:10.1002/cpdd.673

DOI
10.1002/cpdd.673
Journal article

Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials

Corey, G. R., Wilcox, M. H., Gonzalez, J., Jandourek, A., Wilson, D. J., Friedland, H. D., . . . Dryden, M. (2019). Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 53(6), 830-837. doi:10.1016/j.ijantimicag.2019.01.016

DOI
10.1016/j.ijantimicag.2019.01.016
Journal article

Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia

Das, S., Li, J., Riccobene, T., Carrothers, T. J., Newell, P., Melnick, D., . . . Nichols, W. W. (2019). Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(4). doi:10.1128/AAC.02187-18

DOI
10.1128/AAC.02187-18
Journal article

2018

2017

Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014)

Musuamba, F. T., Manolis, E., Holford, N., Cheung, S. Y. A., Friberg, L. E., Ogungbenro, K., . . . Rusten, I. S. (2017). Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014). CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 6(7), 418-429. doi:10.1002/psp4.12196

DOI
10.1002/psp4.12196
Journal article

Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia

Riccobene, T. A., Khariton, T., Knebel, W., Das, S., Li, J., Jandourek, A., . . . Bradley, J. S. (2017). Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia. JOURNAL OF CLINICAL PHARMACOLOGY, 57(3), 345-355. doi:10.1002/jcph.809

DOI
10.1002/jcph.809
Journal article

Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment

Merdjan, H., Tarral, A., Das, S., & Li, J. (2017). Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment. JOURNAL OF CLINICAL PHARMACOLOGY, 57(2), 211-218. doi:10.1002/jcph.793

DOI
10.1002/jcph.793
Journal article

2016

Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients

Bradley, J. S., Armstrong, J., Arrieta, A., Bishai, R., Das, S., Delair, S., . . . Zhoug, D. (2016). Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(10), 6252-6259. doi:10.1128/AAC.00862-16

DOI
10.1128/AAC.00862-16
Journal article

2015

Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens

Nicolau, D. P., Siew, L., Armstrong, J., Li, J., Edeki, T., Learoyd, M., & Das, S. (2015). Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(10), 2862-2869. doi:10.1093/jac/dkv170

DOI
10.1093/jac/dkv170
Journal article

Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects

Das, S., Li, J., Armstrong, J., Learoyd, M., & Edeki, T. (2015). Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects. PHARMACOLOGY RESEARCH & PERSPECTIVES, 3(5). doi:10.1002/prp2.172

DOI
10.1002/prp2.172
Journal article

Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers

Tominaga, N., Edeki, T., Li, J., Learoyd, M., Bouw, M. R., & Das, S. (2015). Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers. JOURNAL OF INFECTION AND CHEMOTHERAPY, 21(8), 551-558. doi:10.1016/j.jiac.2015.04.006

DOI
10.1016/j.jiac.2015.04.006
Journal article

2014

Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-α (TNF-α) using AZD9773, an anti-TNF-α immune Fab, in murine CLP sepsis

Newham, P., Ross, D., Ceuppens, P., Das, S., Yates, J. W. T., Betts, C., . . . McKay, J. S. (2014). Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-α (TNF-α) using AZD9773, an anti-TNF-α immune Fab, in murine CLP sepsis. INFLAMMATION RESEARCH, 63(2), 149-160. doi:10.1007/s00011-013-0683-3

DOI
10.1007/s00011-013-0683-3
Journal article

Assessment of the Mass Balance Recovery and Metabolite Profile of Avibactam in Humans and In Vitro Drug-Drug Interaction Potential

Vishwanathan, K., Mair, S., Gupta, A., Atherton, J., Clarkson-Jones, J., Edeki, T., & Das, S. (2014). Assessment of the Mass Balance Recovery and Metabolite Profile of Avibactam in Humans and In Vitro Drug-Drug Interaction Potential. DRUG METABOLISM AND DISPOSITION, 42(5), 932-942. doi:10.1124/dmd.113.055335

DOI
10.1124/dmd.113.055335
Journal article

Randomized, Placebo-Controlled Study to Assess the Impact on QT/QTc Interval of Supratherapeutic Doses of Ceftazidime-Avibactam or Ceftaroline Fosamil-Avibactam

Das, S., Armstrong, J., Mathews, D., Li, J., & Edeki, T. (2014). Randomized, Placebo-Controlled Study to Assess the Impact on QT/QTc Interval of Supratherapeutic Doses of Ceftazidime-Avibactam or Ceftaroline Fosamil-Avibactam. JOURNAL OF CLINICAL PHARMACOLOGY, 54(3), 331-340. doi:10.1002/jcph.199

DOI
10.1002/jcph.199
Journal article

2013

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors

Schwartz, G. K., Carvajal, R. D., Midgley, R., Rodig, S. J., Stockman, P. K., Ataman, O., . . . Shapiro, G. I. (2013). Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. INVESTIGATIONAL NEW DRUGS, 31(2), 370-380. doi:10.1007/s10637-012-9825-7

DOI
10.1007/s10637-012-9825-7
Journal article

2012

Population pharmacokinetic/pharmacodynamic modelling of the anti-TNF-<i>α</i> polyclonal fragment antibody AZD9773 in patients with severe sepsis

Yates, J. W. T., Das, S., Mainwaring, G., & Kemp, J. (2012). Population pharmacokinetic/pharmacodynamic modelling of the anti-TNF-<i>α</i> polyclonal fragment antibody AZD9773 in patients with severe sepsis. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 39(6), 591-599. doi:10.1007/s10928-012-9270-4

DOI
10.1007/s10928-012-9270-4
Journal article

A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock

Morris, P. E., Zeno, B., Bernard, A. C., Huang, X., Das, S., Edeki, T., . . . Bernard, G. R. (2012). A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock. CRITICAL CARE, 16(1). doi:10.1186/cc11203

DOI
10.1186/cc11203
Journal article

2011

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors

Boss, D. S., Witteveen, P. O., van der Sar, J., Lolkema, M. P., Voest, E. E., Stockman, P. K., . . . Schellens, J. H. (2011). Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. ANNALS OF ONCOLOGY, 22(2), 431-437. doi:10.1093/annonc/mdq344

DOI
10.1093/annonc/mdq344
Journal article